Genprex

Tagged: Aldevron

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

AUSTIN, Texas & CAMBRIDGE, Mass.— (August 6, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018….

Read More

Thermo Fisher and Brammer Bio Deal Illustrates Rapid Growth for Gene Therapy

Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition of Spark Therapeutics, Biogen’s buying of Nightstar Therapeutics and Pfizer’s purchase of Vivet Therapeutics….

Read More